AnewPharma
CompanyChina
AnewPharma develops one asset, in phase 3 (CM082 in renal cell cancer metastatic). Mostly small molecule acting on PDGFRB and KDR; based in China.
- 1
- Asset
- Furthest
- Phase 3
- 3
- Trials
- 0
- Signals
Pipeline
1Multitargeted tyrosine kinase inhibitor targeting VEGFR and PDGFR receptors
Phase 3, Small molecule, PDGFRB, KDR, renal cell cancer metastatic, renal cell carcinoma recurrent (Phase 1)
Full company profiles: pipeline, trials, funding and people.
See ProIn the full profile
- Evidence behind the mechanisms3
- Trials3
- Similar companies6
Updated 10 Oct 2026 · 8 sources